Our group aims to gain a better understanding of the clinical characteristics and mechanisms of progression and therapeutic resistance of hematological tumors with a focus on multiple myeloma and aggressive T and B lymphomas to propose new therapeutic strategies.
The lab is interested in improving the understanding of the molecular mechanisms leading to the progression and therapeutic resistance of multiple myeloma, including extramedullary disease, Hodgkin lymphoma and aggressive non-Hodgkin B and T lymphomas.
To develop these lines of research, we use patient samples and advanced preclinical models for therapeutic, mechanistic and functional studies. We have developed the technology to generate murine models derived from patients by orthotopic implantation (orthotopic PDX) and 2D/3D cultures that we can humanize using components of the human immune system (from the same patient from whom the model has been derived, when possible). Additionally, we are involved in a project that is developing humanized nanomedicines as a new therapeutic strategy for acute myeloid leukemia.
Our group is integrated by professionals from the Clinical Hematology Service of ICO/Hospitalet, the ProCURE/ICO Program and the Pathology Service of the Hospital of Bellvitge. Within the Hematology Service of the ICO Hospitalet, one of our main objectives is to promote translational research training for the professionals of the Service, generating opportunities for the completion of doctoral theses and stimulating new scientific leadership as well as to attract talent with a mixed clinical/researcher profile for the Service.
Group members
Principal Researcher
Principal Researcher
Principal Researcher
Principal Researcher
Principal Researcher
Clinical collaborator
Clinical collaborator
Clinical collaborator
Clinical collaborator
Predoctoral researcher
Posdoctoral researcher
Publications
N Engl J Med. 2023 Jul 13;389(2):148-157. doi: 10.1056/NEJMoa2301665. Epub 2023 Jun 5. ABSTRACT BACKGROUND: In an analysis of the primary outcome of this phase 3 trial, patients with early relapsed or refractory large B-cell lymphoma who received axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor T-cell therapy, as second-line treatment had significantly longer […]
Blood Cell Ther. 2022 Dec 23;5(Spec Edition):S15-S24. doi: 10.31547/bct-2022-013. eCollection 2022 Dec 23. ABSTRACT A variety of cellular therapies including hematopoietic cell transplantation (HCT) hold the promise to treat medical conditions and diseases that currently have limited or no effective therapeutic options. A number of cellular therapies other than HCT, such as CAR T-cell therapy, […]
Leukemia. 2023 Jul;37(7):1511-1520. doi: 10.1038/s41375-023-01924-x. Epub 2023 May 8. ABSTRACT Natural killer/T-cell lymphomas (NKTCL) represent rare and aggressive lymphoid malignancies. Patients (pts) with relapsed/refractory disease after Asparaginase (ASPA)-based chemotherapy have a dismal prognosis. To better define the role of allogeneic hematopoietic stem cell transplantation (allo-HSCT), we conducted a retrospective analysis of data shared with the […]
Bone Marrow Transplant. 2023 Aug;58(8):881-892. doi: 10.1038/s41409-023-01998-2. Epub 2023 May 6. ABSTRACT We previously analyzed trends in incidence and factors associated with lethal complications in ALL/AML/CML patients (causes of deaths; COD-1 study). The objective of this study was the analysis of incidence and specific causes of death after HCT, with focus on infectious deaths in […]
Hemasphere. 2023 Apr 27;7(5):e889. doi: 10.1097/HS9.0000000000000889. eCollection 2023 May. ABSTRACT Hematological toxicity represents the most common grade ≥3 toxicity after chimeric antigen receptor (CAR) T-cell therapy. However, its underlying pathophysiology is incompletely understood and its grading and management remains ill-defined. To inform the forthcoming European Hematology Association/European Society for Blood and Marrow Transplantation (EHA/EBMT) guidelines […]
Research Projects
PI21/00684. Improving Outcomes of Patients with Extramedullary Multiple Myeloma. Potential Applicability of Orthoxenograft Models in the Study of Genetic Bases of Drug Resistance. ISCIII/AES. Budget: 135.520,00 euros, 2022 – 2024. PI: Anna Sureda, Co-PI: Lourdes Farre.
201941-30. Humanized nanomedicines selectively killing CXCR4+ cancer cells for Acute Myeloid Leukemia therapy. Marató TV3. Budget: 99.960,81 euros, 2020 – 2024. Projecte coordinat. Sub-projecte PI: Dra. Lourdes Farre
Collaborations
Isolda Casanova. Institut de Recerca del Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Toni Villaverde. Institut de Biotecnologia i de Biomedicina. Universitat Autònoma de Barcelona, Bellaterra, Spain
Sonia Guil. Josep Carreras Leukaemia Research Institute, Badalona, Spain.
Campus IDIBELL
(L’Hospitalet del Llobregat)
Hospital Duran i Reynals, Gran Via 199,
L’Hospitalet del Llobregat,
Barcelona 08908
Tel. +34 93 260 7952
Campus IGTP-IJC
(Badalona)
Campus Can Ruti – IGTP – Building Muntanya,
Rd. Can Ruti, Camí de les escoles s/n,
Badalona, Barcelona 08916
Tel. +34 93 554 3069
Campus IDIBGI
(Girona)
Parc Hospitalari Martí i Julià de Salt, Dr. Castany s/n,
Salt, Girona 17190
Tel. +34 872 987 087
Casanovas’ Lab